Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

Novartis building

Novartis offloads diagnostics unit to Grifols for $1.7bn

Part of strategy to focus on more profitable businesses

- PMLiVE

EMA on track with biosimilars guidance says industry

Updates expected to build confidence among healthcare professionals and patients

- PMLiVE

Novartis debates future of Horsham site

UK research centre could close

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

- PMLiVE

Change at the top as Levin leaves Teva

CEO resigns amid company-wide restructure

- PMLiVE

CHMP names France’s Pierre Demolis vice-chair

He is director of the oncology and haematology division at the ANSM

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Union pressure delays Teva’s Israeli layoffs

Workforce cuts put on hold

- PMLiVE

Novartis adds Facebook personalisation to sight campaign

Features the viewer's own pictures from the social network

- PMLiVE

Teva cuts 5,000 jobs to save $2bn a year by 2017

Israeli pharma company accelerates cost-reduction plans

Novartis building

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links